Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Use of All-trans Retinoic Acid in Combination with Arsenic Trioxide for Remission Induction in Patients with Newly Diagnosed Acute Promyelocytic Leukemia and for Consolidation/Maintenance in CR Patients

Use of All-trans Retinoic Acid in Combination with Arsenic Trioxide for Remission Induction in... In the present study, 90 patients with newly diagnosed acute promyelocytic leukemia (APL) were studied for all-trans retinoic acid (ATRA) and arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) combination treatment in remission induction and postremission therapy. In addition, 20 APL patients who had achieved complete remission (CR) with an ATRA-based regimen received ATRA/As<sub>2</sub>O<sub>3</sub> combination for consolidation and maintenance were also enrolled. The results showed that ATRA/As<sub>2</sub>O<sub>3</sub> combination therapy yielded a high CR rate of 93.3% and a significantly shorter time to enter CR (median: 31 days; range: 18–59 days) compared to the ATRA-based regimen (n = 72; median: 39 days; range: 25–62 days). With the ATRA/As<sub>2</sub>O<sub>3</sub> combination for CR maintaining, regardless of the way by which CR was attained, the relapse-free survival was significantly better than with an ATRA plus cytotoxic chemotherapy regimen (92.9 ± 3.2% vs. 72.4 ± 7.6%, for the 3-year Kaplan-Meier estimate of relapse-free survival). The drug toxicity profile showed that with the use of As<sub>2</sub>O<sub>3</sub>, the incidence of hepatotoxicity was obviously high during remission induction but decreased significantly during postremission treatment. We conclude that APL patients may benefit from the early use of the combination of ATRA and As<sub>2</sub>O<sub>3</sub>, in either remission induction or consolidation/maintenance. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Haematologica Karger

Use of All-trans Retinoic Acid in Combination with Arsenic Trioxide for Remission Induction in Patients with Newly Diagnosed Acute Promyelocytic Leukemia and for Consolidation/Maintenance in CR Patients

Download PDF
9 pages

Loading next page...
 
/lp/karger/use-of-all-trans-retinoic-acid-in-combination-with-arsenic-trioxide-5LEXMT3MAR

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Karger
Copyright
© 2009 S. Karger AG, Basel
ISSN
0001-5792
eISSN
1421-9662
DOI
10.1159/000204472
Publisher site
See Article on Publisher Site

Abstract

In the present study, 90 patients with newly diagnosed acute promyelocytic leukemia (APL) were studied for all-trans retinoic acid (ATRA) and arsenic trioxide (As<sub>2</sub>O<sub>3</sub>) combination treatment in remission induction and postremission therapy. In addition, 20 APL patients who had achieved complete remission (CR) with an ATRA-based regimen received ATRA/As<sub>2</sub>O<sub>3</sub> combination for consolidation and maintenance were also enrolled. The results showed that ATRA/As<sub>2</sub>O<sub>3</sub> combination therapy yielded a high CR rate of 93.3% and a significantly shorter time to enter CR (median: 31 days; range: 18–59 days) compared to the ATRA-based regimen (n = 72; median: 39 days; range: 25–62 days). With the ATRA/As<sub>2</sub>O<sub>3</sub> combination for CR maintaining, regardless of the way by which CR was attained, the relapse-free survival was significantly better than with an ATRA plus cytotoxic chemotherapy regimen (92.9 ± 3.2% vs. 72.4 ± 7.6%, for the 3-year Kaplan-Meier estimate of relapse-free survival). The drug toxicity profile showed that with the use of As<sub>2</sub>O<sub>3</sub>, the incidence of hepatotoxicity was obviously high during remission induction but decreased significantly during postremission treatment. We conclude that APL patients may benefit from the early use of the combination of ATRA and As<sub>2</sub>O<sub>3</sub>, in either remission induction or consolidation/maintenance.

Journal

Acta Haematologica – Karger

Published: Jan 1, 2009

Keywords: Arsenic trioxide; All-trans retinoic acid; Remission induction; Maintenance; Relapse-free survival; Acute promyeolytic leukemia

There are no references for this article.